NRXP earnings analysis
What we found in NRXP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q excerpt is principally compliance and other-information content and does not include the financial statements, MD&A, balance sheet, cash flow statement, or segment data needed to assess quarterly operating trends. Controls were deemed effective as of June 30, 2026, with no unregistered equity sales or senior-security defaults during the three and six months ended that date. No material risk-factor changes were reported versus the 2025 Form 10-K, and no quantitative guidance was provided in the supplied text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls deemed effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance over required disclosures.
- Financial reporting controls effective
- Management concluded that internal control over financial reporting was effective as of June 30, 2026, under the COSO 2013 framework.
- No unregistered equity sales
- The company reported no unregistered sales of equity securities during the three and six months ended June 30, 2026 that had not been previously reported.
- No senior-security defaults
- The company reported no defaults upon senior securities during the three and six months ended June 30, 2026 that had not been previously reported.
- No insider trading-plan changes
- No directors or executive officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three and six months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Existing 10-K risks remain applicable
- The company stated that there were no material changes to the risk factors disclosed in its 2025 Form 10-K, filed March 23, 2026. Existing risks therefore remain applicable despite no identified update in this 10-Q.
- Residual control risk remains
- Internal controls provide only reasonable assurance and may be circumvented through collusion or management override; management nevertheless assessed controls as effective as of June 30, 2026.
- Legal-proceeding exposure unclear
- The filing directs investors to Note 10 for certain legal proceedings as of and for the six months ended June 30, 2026, but the supplied excerpt does not provide the nature or potential exposure of those proceedings.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; outlook may be addressed in a separate earnings release or conference call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- NRx Pharmaceuticals reported Q1 2026 revenue of approximately $1.1 million, primarily from the clinical services provided post-acquisition of Dura. Net loss for the quarter was reduced to $1.4 million from $5.5 million…
- 10-K · March 23, 2026
- NRx Pharmaceuticals reported a fourth quarter revenue of $983,000, significantly below consensus estimates of $7.03 million while achieving an EPS of $0.20, beating expectations of -$0.08. The company continues to…
- 10-Q · November 14, 2025
- NRX Pharmaceuticals reported disappointing results for Q3 2025, with revenues falling drastically short of expectations. Actual revenue was only $242,000 compared to an estimated $10.85 million, and reported EPS was…
- 10-Q · August 18, 2025
- NRx Pharmaceuticals reported Q2 2025 results with an EPS of -$0.98, significantly missing the consensus estimate of -$0.23 and maintaining zero revenue. The company posted a net loss of $17.6 million, a drastic increase…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NRXP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever